Get the Stockscreener App
33.02
0.82%
0.27
Immunocore Holdings Plc Adr stock is traded at $33.02, with a volume of 121.19K.
It is up +0.82% in the last 24 hours and down -14.54% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$32.75
Open:
$32.72
24h Volume:
121.19K
Relative Volume:
0.29
Market Cap:
$1.80B
Revenue:
$345.60M
Net Income/Loss:
$-79.01M
P/E Ratio:
-20.58
EPS:
-1.6045
Net Cash Flow:
$-18.62M
1W Performance:
+3.12%
1M Performance:
-14.54%
6M Performance:
+10.58%
1Y Performance:
-8.33%
1-Day Range:
$32.60
$33.06
1-Week Range:
$30.76
$33.95
52-Week Range:
$23.15
$41.54
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
33.02 | 1.80B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Deutsche Bank | Buy |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-24-24 | Initiated | UBS | Sell |
| Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-23 | Initiated | Robert W. Baird | Outperform |
| Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-13-23 | Initiated | Needham | Buy |
| Aug-16-23 | Initiated | CapitalOne | Overweight |
| Jul-17-23 | Initiated | Canaccord Genuity | Hold |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-30-23 | Initiated | Guggenheim | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-30-22 | Initiated | Barclays | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
| Aug-08-22 | Initiated | Cowen | Outperform |
| Aug-02-22 | Initiated | BTIG Research | Buy |
| Feb-08-22 | Initiated | H.C. Wainwright | Buy |
| Oct-20-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | Goldman | Neutral |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
| Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet - Yahoo Finance
Mizuho cuts Immunocore stock price target to $33 from $38 - Investing.com
Immunocore stock hits 52-week low at $27.19 amid market challenges By Investing.com - Investing.com South Africa
Immunocore stock hits 52-week low at $27.19 amid market challenges - Investing.com
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $100 target on Immunocore stock - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
PBYI Stock Rises as Q4 Earnings & Sales Outpace EstimatesFebruary 28, 2025 - Zacks Investment Research
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):